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ABSTRACT
Objectives: To estimate the cost-effectiveness of temsirolimus compared
to interferon-a for ﬁrst line treatment of patients with advanced, poor
prognosis renal cell carcinoma, from the perspective of the UK National
Health Service.
Methods: A decision-analytic model was developed to estimate the cost-
effectiveness of temsirolimus. The clinical effectiveness of temsiro-
limus compared with interferon-a and the utility values (using EQ-5D
tariffs) were taken from a recent phase III randomized clinical trial.
Cost data were obtained from published literature and based on current
UK practice. The effect of parameter uncertainty on cost-effectiveness
was explored through extensive one-way and probabilistic sensitivity
analyses.
Results: Compared to interferon-a, temsirolimus treatment resulted in an
incremental cost per QALY gained of £94,632; based on an estimated
mean gain of 0.24 quality-adjusted life years (QALYs) per patient, at a
mean additional cost of £22,331 (inﬂated to 2007/8). The cost per QALY
for patient subgroups ranged from £74,369 to £154,752. The probability
that temsirolimus is cost-effective compared to interferon-a at a willing-
ness to pay threshold of £30,000 per QALY for all patient groups is
expected to be close to zero. The cost per QALY was sensitive to the
clinical effectiveness parameters, health state utilities, drug costs and the
cost of administration of temsirolimus.
Conclusions: Temsirolimus has been shown to be clinically effective com-
pared to interferon-a offering additional health beneﬁts, however, with a
cost per QALY in excess of £90,000, it may not be regarded as a cost-
effective use of resources in some health care settings.
Keywords: cost-effectiveness, cost-utility, decision analytic modeling, renal
cell carcinoma, temsirolimus, Torisel.
Introduction
Renal cell carcinoma (RCC) is a highly vascular type of kidney
cancer, often asymptomatic until it reaches a late stage. Meta-
static spread may involve the lymph nodes, lung, bones, liver,
brain and other organs. In England and Wales, kidney cancer is
the eighth most common cancer in males and the fourteenth most
common cancer in females [1]. In 2004, there were 5745 regis-
trations of newly diagnosed kidney cancer in England and Wales
[1,2]. The prognosis following diagnosis of metastatic RCC is
poor. In England and Wales approximately 90% of people diag-
nosed with Stage IV RCC die within ﬁve years of diagnosis,
where tumour Stage, increasing in severity from I to IV, is based
on the combination of tumour size and extent of spread from the
kidneys [3]. Until recently, treatment options for metastatic RCC
have comprised radical nephrectomy and immunotherapy (i.e.,
interferon-a in the UK [3]. Nevertheless, a number of new phar-
macological therapies (sunitinib, bevacizumab, sorafenib and
temsirolimus) have been licensed for treatment of RCC, across
speciﬁc indications. These drugs offer health beneﬁts to patients
with RCC (3), but due to their relatively high cost their cost-
effectiveness may be questioned [4]. In this article, we present
cost-effectiveness analysis for one of these new drugs, temsiroli-
mus, compared with interferon-a.
Temsirolimus is a selective inhibitor of the mammalian target
of rapamycin and is licensed for ﬁrst line treatment of patients
with advanced RCC who have at least three of six poor prog-
nostic risk factors. A recent phase III randomized clinical trial
demonstrated the survival beneﬁt of temsirolimus over
interferon-a [5].
The cost-effectiveness of treatment with temsirolimus in this
patient group has not previously been published, although
Wyeth, the manufacturer of temsirolimus, recently made a sub-
mission to the National Institute of Health and Clinical Excel-
lence (NICE) which included a cost-effectiveness analysis for
temsirolimus compared to interferon-a [4]. The decision analytic
model, and subsequent cost-effectiveness analysis, presented here
formed part of the independent assessment report submitted to
NICE (by the authors) and were used to inform the NICE Health
Technology Appraisal process.
Methods
Model Structure
An “area under the curve” decision-analytic model was devel-
oped to model disease progression in RCC and the treatment
effectiveness of temsirolimus versus interferon-a. Using this
model, we have estimated the cost-effectiveness of temsirolimus
versus interferon-a for ﬁrst line treatment of patients with
advanced RCC deemed to have poor prognosis (deﬁned in
[3,6,7]). Subsequent second-line treatments, such as sunitinib
and sorafenib, are not explicitly modelled (see Discussion). The
model uses techniques from survival analysis to consider progres-
sion of RCC in a cohort of patients over time. The model was
written in Microsoft Excel (Microsoft Corporation, Redmond,
WA). The structure of the model was informed by a review of the
available literature, clinical guidelines for treatment of RCC, and
expert opinion on the clinical progression of the disease [3].
At any time, a patient is assumed to be in one of three health
states: progression-free survival (PFS), progressive disease (PD)
and death. Patients move between states during each cycle. All
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patients enter the model in PFS, having been diagnosed with
advanced/metastatic RCC. Patients remain in PFS until disease
progression or death. Once patients enter PD, they remain there
until death. The model uses estimates of effectiveness, costs and
health state values against these health states to model progres-
sion of disease and cost-effectiveness over time. The model uses a
10-year time horizon (effectively lifetime because virtually all
simulated patients are dead at 10 years), and a 6-week model
cycle (short enough to capture all clinical events). This structure
is simple, but appropriate for capturing the disease progression
of RCC. Future costs and beneﬁts are discounted at 3.5% per
year [8].
For both interferon-a and temsirolimus, separate Weibull
curves are used to predict the number of patients alive over time
and the number of patients in PFS over time. The number of
patients in progressive disease is then estimated as the number
alive minus the number in PFS. To model disease progression for
the baseline treatment (interferon-a, Weibull curves were ﬁtted
separately to the PFS and OS Kaplan-Meier aggregate data
reported by Hudes et al. [5] Whilst individual patient data may
yield a more accurate assessment of treatment effectiveness, this
information is unpublished (see Discussion). Weibull curves were
chosen because they ﬁtted the Kaplan-Meier data as well as, or
better, than other functions, as measured by the R2 statistic: 96%
for PFS and 99% for OS. Modelling of survival data used the
standard technique of regressing log(-log(S(t))) against log(t),
where S(t) is the survival function at time t [9,10]. The ﬁt of the
estimated Weibull functions were inspected for reasonableness.
Disease progression for those treated with temsirolimus was
modelled by applying the appropriate hazard ratio to the curve
for interferon-a [10], i.e., the survival curve for temsirolimus
equals the survival curve for interferon-a raised to the power of
the hazard ratio. Therefore, the Weibull parameter gamma (a for
temsirolimus was set equal to a for interferon-a, and the Weibull
parameter lambda (a for temsirolimus was calculated as a for
interferon-a multiplied by the hazard ratio between the two
treatments. This method allows for uncertainty in the hazard
ratios for the probabilistic sensitivity analysis.
Given the number of patients for each treatment in each of
the health states at each model cycle, the total discounted costs
and beneﬁts were calculated as follows. The cost estimated at
each cycle was calculated as the sum over the PFS and PD health
states of the product of the number of patients in the state and
the cost incurred in that state over the cycle. The total discounted
cost was calculated as the sum over all cycles of the discounted
costs in each cycle. The total discounted quality-adjusted life-
years (QALYs) was calculated similarly. The QALYs in each cycle
were calculated as the sum over the PFS and PD health states of
the products of the number of patients in the state and the utility
in that health state divided by the number of cycles per year.
Half-cycle corrections were applied by calculating the average
number of patients over each model cycle in each health state.
Clinical Effectiveness
Clinical effectiveness data were taken from the randomised clini-
cal trial reported by Hudes et al. [5], a multinational, multi-
centre, randomized, controlled clinical trial. A systemic review of
the literature revealed that this was the only phase III trial of
temsirolimus in the appropriate patient population [3]. There-
fore, this was the only choice of effectiveness evidence. In
particular, an extended evidence network or mixed treatment
comparison was not relevant. The Weibull curves ﬁtted to
progression-free survival and overall survival for interferon-a
and temsirolimus are shown in Figure 1. They are derived from
the Weibull parameters shown in Table 1. The survival curves for
temsirolimus do not ﬁt the Kaplan-Meier curves as well as for
interferon-a. Nonetheless, there are two important advantages of
using the hazard ratios to derive the temsirolimus curves, as
opposed to ﬁtting the temsirolimus curves independently of the
interferon-a curves and cited hazard ratios. First, the method
allows for the number of patients at risk on the Kaplan-Meier
curve, and second, it allows for modelling of uncertainty in
treatment effectiveness via uncertainty in the hazard ratios. Clini-
0.00
0.25
0.50
0.75
1.00
0 5 10 15 20 25 30
Time (months)
S
u
rv
iv
al
OS IFN
PFS IFN
PFS TEM
OS TEM
Figure 1 Weibull curves ﬁtted to interferon-a
and temsirolimus progression-free survival (PFS)
and overall survival (OS) Kaplan-Meier data.
Table 1 Weibull parameters for progression-free survival and overall
survival for interferon-a and temsirolimus
Parameter Interferon-a Temsirolimus
Progression-free survival l 0.542 0.401
g 0.582 0.582
Overall survival l 0.127 0.092
g 0.829 0.829
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cal results and patient enrollment are described in detail in the
trial paper [5]. In brief, 626 patients with stage IV or recurrent
RCC, and with no previous systemic therapy, were randomized
to receive either temsirolimus (209 patients), interferon-a (207
patients), or interferon-a and temsirolimus (210 patients). We
have considered only those patients taking either temsirolimus or
interferon-a. The median age of patients was 59 years, and 69%
were male. Most patients (81%) had clear-cell RCC, the remain-
der non-clear-cell RCC. Sixty-seven percent of patients had had a
prior nephrectomy. Although all participants met the trial inclu-
sion criteria for poor prognosis, approximately one quarter
(27%) were deemed to have intermediate prognosis according to
the more widely used MSKCC indicator of prognosis described
by Motzer et al. [6,7]. Temsirolimus (25 mg i.v.) was adminis-
tered once per week. Interferon-a started at a dose of 3MU three
times per week in the ﬁrst week. The dose was raised to 9MU
three times per week in the second week and 18MU three times
per week in week 3 if this dose was tolerated. Both drugs were
administered until disease progression, symptomatic deteriora-
tion or intolerable adverse events.
Effectiveness data (hazard ratios) are shown in Table 2. Pro-
gression free and overall survival were statistically signiﬁcantly
better for temsirolimus compared to interferon-a for all patients
combined. We also considered several patient subgroups: people
with clear-cell RCC, people who had undergone prior nephrec-
tomy, and those with no prior nephrectomy. For these subgroups,
in the absence of baseline data, we assumed the same baseline
interferon-a PFS and OS curves as for all patients in the RCT [5],
and we estimated the temsirolimus PFS and OS curves by appli-
cation of the subgroup-speciﬁc hazard ratios given in Table 2. We
felt that due to the uncertainty in the estimates of PFS for people
with non-clear-cell RCC derived from the RCT, effectiveness in
this patient subgroup remained unproven and therefore a formal
cost-effectiveness analysis was inappropriate.
Health State Utilities
A systematic review of the literature identiﬁed a single study
reporting health state utilities for RCC [11]. These utilities were
collected during a RCT of sunitinib versus interferon-a. In their
submission to NICE, Wyeth presented health state utilities
derived from EQ-5D data collected during the Phase III RCT [5].
These data were not reported in the publication of the trial,
although some brief detail has been presented in a conference
abstract [3]. We used these health state utilities of 0.60 (s.e.
estimated as 10% of mean, i.e., 0.06) for PFS and 0.45 (s.e.
estimated as 10% of mean, i.e., 0.04) for PD in our model.
These values were used, as opposed to those from the sunitinib
RCT [11], because they better reﬂect the patient population
(advanced, poor prognosis RCC).
Resource Use and Costs
The perspective for costs is that of the UK NHS and Personal
Social Services. There is an absence of published data to inform
on the costs associated with treatment of RCC. Assumptions
were based on guidelines outlining current practice and informa-
tion provided by clinical experts (see Acknowledgements). The
prices of temsirolimus and interferon-a were taken from the
British National Formulary (BNF) [12], (Table 3).
We have assumed that compliance with the drugs in the
model would not be 100% due to withdrawals and dose reduc-
tions. We have deﬁned the dose intensity as the amount of drug
administered as a proportion of the amount that would have
been administered if there had been no patient withdrawals or
dose reductions. This is in line with the use of effectiveness data
collected on an intention-to-treat basis. We assumed the same
dose intensities as reported in the RCT reported by Hudes et al.
[5], namely, 92% for temsirolimus and 56% for interferon-a.
These dose intensities are used to reduce the cost of temsirolimus
and interferon-a. The values are rather uncertain because they
were measured in the ﬁrst eight weeks of treatment only. There-
fore, we investigated the impact of varying the values in the
sensitivity analysis. In the RCT, the dose of interferon-a was
raised to 18MU (million units per ml) only if this was tolerated
[5]. Otherwise, patients received the highest tolerable dose: 3,
4.5 or 6MU. This explains the low (56%) dose intensity of
interferon-a.
Table 2 Hazard ratios of temsirolimus vs. interferon-a by subgroup
Subgroup Number of patients Survival Hazard ratio (95% CI) Data source
All data 416 PFS 0.74 (0.60–0.91) [3]
OS 0.73 (0.58–0.92) [5]
Clear-cell/non-clear-cell Clear-cell = 339 PFS Clear cell = 0.84 (0.67–1.05), [21]
Not–clear cell = 0.36 (0.22–1.59)
Non-clear-cell = 77 OS Clear = 0.85 (0.64–1.06), [21]
Not–clear cell = 0.55 (0.33–0.90)
Prior nephrectomy (Y/N) Yes = 278, No = 138 PFS Yes 0.74 (0.58–0.95), [3]
No 0.63 (0.44–0.91)*
OS Yes 0.84 (0.63–1.11), [3]
No 0.61 (0.41–0.91)
* Investigator assessment.
CI, conﬁdence interval; OS, overall survival; PFS, progression-free survival.
Table 3 Drug costs
Drug Brand Dose and frequency Cost* Cost per 6-week cycle
Interferon-a (18 MU) Roferon-A 18 MU† 3 times per week £90.39 per 18 MU‡ £1265 ﬁrst model cycle,
£1627 future cycles
Temsirolimus Torisel 25 mg once per week £620 per dose§ £3720§
*Drug costs are taken from British National Formulary (BNF) No. 57, [12].
†3 million units/mL (MU) per dose in ﬁrst week, 9 MU per dose in second week, 18 MU per dose thereafter.
‡3 MU dose costs £15.07, 6 MU dose costs £30.12, 9 MU per dose costs £45.19, 18 MU dose costs £90.39.
§Assumes some wastage of temsirolimus given that all 30 mg in a vial is used.
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Within the model, non-drug costs include the cost of drug
administration in PFS, medical management (CT scans, monitor-
ing, blood tests) in PFS, best supportive care in PD and death
(used in sensitivity analysis) (Table 4). All non-drug costs were
inﬂated to 2007/8 values using the Hospital & Community
Health Services Pay and Prices Index [13]. The cost of adminis-
tration of temsirolimus is greater than the cost of administration
of interferon-a, as temsirolimus is administered in hospital,
whereas interferon-a is administered at home (UK current prac-
tice). For interferon-a, we assume that 25% of injections are
administered by a district nurse, the remainder administered by
the patient, a friend or relative (Table 4). The costs of medical
management are generally small relative to the costs of drug
administration. The cost of administration of drugs has not been
adjusted according to dose intensity. This assumption is based on
clinical practice, i.e., that doses of interferon-a are reduced,
rather than omitted completely.
Costs associated with adverse events were not included in the
model. Grade 3 and 4 adverse events are those expected to result
in signiﬁcant health-care costs, but no meaningful difference was
noted in the RCT [5].
Sensitivity Analyses
One-way sensitivity analyses and probabilistic sensitivity analy-
ses were performed by varying effectiveness, utility and costs
parameters. One thousand simulations of the model were run in
the probabilistic sensitivity analysis. For the probabilistic sensi-
tivity analysis, hazard ratios followed lognormal distributions,
utilities followed beta distributions [14] and non-drug costs
followed gamma distributions [14]. For each treatment, we
assumed that the OS and PFS hazard ratios were perfectly cor-
related. This gives the intuitively reasonable result that when the
PFS hazard ratio is simulated to be particularly low (and hence
temsirolimus PFS particular long), then the OS hazard ratio is
simulated to be particularly low (and hence temsirolimus OS
particular long), and vice versa. We imposed the constraint that
at any time t, the number of patients in PFS was limited to the
number of patients alive. The two parameters of the Weibull
distribution, ln(l) and g, for baseline interferon-a PFS and sepa-
rately for OS were drawn from bivariate normal distributions,
using the method of Cholesky matrix decomposition. The
variance-covariance matrices used in the matrix decomposition
were estimated from linear regression of ln(-lnS(t)) against ln(t),
described above, where S(t) is the survival function at time t.
Results
The primary outcome of the analysis was the cost per incremen-
tal QALY gained. For temsirolimus compared to interferon-a we
estimate an incremental gain of 0.24 QALYs, at an additional
cost of £22,331 per patient, giving an incremental cost-
effectiveness ratio of £94,632 per QALY (Table 5). Subgroup
results are given in Table 6. The incremental cost per QALY
varied from £74,369 for patients with no prior nephrectomy to
£154,752 for patients with prior nephrectomy.
The cost per QALY is particularly sensitive to the hazard ratio
for overall survival and to a lesser extent to the hazard ratio for
progression-free survival (Table 7). As expected, when the hazard
ratio for overall survival is reduced (greater beneﬁt of temsiroli-
mus), the cost per QALY decreases. Nevertheless, when the
hazard ratio for progression-free survival is reduced (greater
beneﬁt), the cost per QALY increases. This is because most costs,
in particular drug costs, are incurred in PFS, and incremental
costs in PFS are positive. This factor outweighs the utility gains
associated with additional time in PFS compared to PD. If we set
Table 4 Nondrug costs
Cost item Treatment Base-case cost
Base-case cost per 6-week
model cycle (s.e.)§ Source
Drug administration interferon-a* £25 per district nurse visit, nurse
injects 25% patients†.
3 administrations per week.
£112 (£7) Schema 9.1 Community nurse (includes district
nursing sister, district nurse) [22].
temsirolimus £197 per administration.
1 administration per week.
£1179 (£105) “Chemotherapy Outpatients.” HRG code =
SB15Z. “Deliver subsequent elements of a
chemotherapy cycle” [13].
CT scans interferon-a* and
temsirolimus
£140 per scan, 1 scan every 3
months
£65 (£3) Specialty code RBD1. “Band D1 – CT”. £129 per
scan, £135 [23], inﬂated to 2007/2008.
Monitoring interferon-a* and
temsirolimus
£111 per consultant visit, 1 visit per
month
£154 (£8) Specialty code 370. “Consultant-led follow-up
attendance without treatment outpatient face
to face” [13].
Blood tests interferon-a* and
temsirolimus
£3 per test, 1 test per month £4 (£0) Specialty code DAP823. Haematology [Excluding
Anti-Coagulant Services] [13].
BSC in PD interferon-a* and
temsirolimus
£35 per GP visit, 1 visit per month
£86 per community nurse visit,
1.5 visits per month
Morphine Sulphate
£5 per pack, 1 dose per day¶
£435 (£22)¶ GP visit (consultation lasting 11.7 minutes, with
qualiﬁcation costs, including direct care staff
costs) [22].
Cost per community nurse visit, Band 2 –
Palliative/Respite Care:Adult: Face-to-Face Total
Contacts NHS [13], inﬂated to 2007/2008.
Morphine Sulphate
£5 per pack, 1 dose per day.
(Nonproprietary); 1 mg/mL, net price 50-mL
vial preﬁlled syringe £5.00 per pack [12]¶
Death interferon-a* and
temsirolimus
£0‡ n/a n/a‡
*Roferon-A.
†All ﬁve member of our expert advisory group state that interferon-a is given at home, with, on average 25% (12% s.e.) of injections administered by a district nurse.
‡As a sensitivity analysis, we assumed a cost of £3923, taken from Coyle et al. (1999) [24], averaged over hospital and hospice stays = £2701, revalued to 2007/2008.
§Standard errors (s.e.) were calculated from the interquartile ranges and number of data submissions given in [13] and [23], except for the costs taken from [22], the cost of best supportive
care in progressive disease and the cost of administration of interferon-a, which were estimated by assuming the average ratio of standard error to mean, 0.06, over all other costs.
¶As a sensitivity analysis, we assumed a cost of £937 per month for hospital and hospice care, based on a study of costs of managing women with stage IV breast cancer in the UK [25]. Mostly
medication, scans, tests, hospitalization, outpatient visits.
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the utility in PD far lower than the utility in PFS, when we reduce
the PFS HR, the increased utility difference outweighs the addi-
tional incremental costs, and the ICER decreases. The cost-
effectiveness of temsirolimus is also highly sensitive to the choice
of utilities, the cost of temsirolimus, and the cost of administra-
tion of temsirolimus. The ICER is only marginally inﬂuenced by
the other parameters, including discounting, time horizon, drug
dose intensities (which are uncertain) and non-drug costs.
At a willingness to pay threshold of £30,000 per QALY, the
probability that temsirolimus is cost-effective compared to
interferon-a is expected to be close to zero for all patients com-
bined (Fig. 2) and for all patient subgroups studied. In the base-
case, we assume that the OS and PFS hazard ratios are perfectly
correlated. When we assume that they are perfectly uncorrelated,
uncertainty in cost-effectiveness increases, but the probability
that temsirolimus is cost-effective compared to interferon-a is
still 0.0% at a willingness to pay threshold of £30,000/QALY,
and the willingness to pay threshold at the 50% probability that
temsirolimus is cost-effective is virtually unchanged at about
£95,000/QALY.
Discussion
Treatment of patients with advanced, poor-prognosis RCC
with temsirolimus has been shown to be clinically effective [5].
Nevertheless, due to the balance of costs and beneﬁts, the cost-
effectiveness of temsirolimus may be questioned [4]. The base-
case ICERs of £94,632 per QALY for the general patient group
and £74,369 to £154,752 per QALY for the patient subgroups
do not support the use of temsirolimus when considered against
published guidance from decision making bodies in the UK NHS
[8], and in other countries [15–17]. Nevertheless, policymakers
may be more likely to publicly fund temsirolimus for the follow-
ing reasons: temsirolimus is an orphan drug [18], and patients
with poor prognosis advanced RCC have a very short life expect-
ancy and no other effective treatment options.
Table 5 Base-case discounted per patient mean costs and effects
Interferon-a Temsirolimus
Temsirolimus
vs. interferon-a
Life years 1.07 1.52 0.45
QALYs 0.53 0.77 0.24
Time on treatment (months) 4.6 7.6 3.0
Drug cost £2,823 £18,036 £15,213
Drug admin £367 £6,215 £5,848
Medical management* £729 £1,176 £447
BSC in PD £2,599 £3,422 £822
Total costs £6,519 £28,849 £22,331
Cost/LYG £49,701
Cost/QALY £94,632
* CT scans, monitoring, blood tests.
BSC, best supportive care; CT, computed tomography; LYG, life years gained; PD, progressive
disease; QALY, quality-adjusted life year.
Table 6 Base-case discounted per patient cost-effectiveness for patient
subgroups
Subgroup Cost (£)/LYG ICER (£/QALY)
Clear-cell £80,229 £150,721
Prior nephrectomy £92,769 £154,752
No prior nephrectomy £39,198 £74,369
LYG, life years gained; QALY, quality-adjusted life year.
Table 7 Results of sensitivity analysis
Base-case Sensitivity analysis
ICERtemsirolimus
vs. interferon-a
General
Base-case n/a n/a £94,632
Time horizon 10 years 5 years £105,798
Discounting 3.5% p.a. costs and beneﬁts 0% p.a. costs and beneﬁts £90,072
Efﬁcacy
HR PFS 0.74 0.60 (lower 95% CI) £114,878
0.91 (upper 95% CI) £75,591
HR OS 0.73 0.58 (lower 95% CI) £56,589
0.92 (upper 95% CI) £254,146
Costs
Cost of temsirolimus £620 per vial £465 per vial (25% reduction) £75,523
£372 per vial (40% reduction) £64,058
Cost of death £0 £3,923 £94,302
BSC cost in PD (per 6-weeks) £435 £1,297* £101,545
Cost interferon-a admin (per 6 weeks) £112 £0 £96,187
£224 £93,076
Cost temsirolimus admin (per 6 weeks) £1179 £0 £68,292
£2,359 £120,971
Cost monitoring outpatient appointment (per 6 weeks) £154 £0 £93,324
£308 £95,939
Cost CT scan (per 6 weeks) £65 £0 £94,082
£130 £95,182
Dose intensity 92% temsirolimus, 56% interferon-a 100% both treatments £91,878
Utilities
Utilities 0.60 PFS, 0.78 PFS, 0.70 PD† £67,060
0.45 PD PFS utility 0.48 (lower 95% CI) £107,233
PFS utility 0.72 (upper 95% CI) £84,681
PD utility 0.37 (lower 95% CI) £101,785
PD utility 0.52 (upper 95% CI) £88,571
*Based on Remak & Brazil (2004) [25].
†Taken from Motzer et al. (2007) RCT [26].
BSC, best supportive care; CI, conﬁdence interval; CT, computed tomography; HR PFS, hazard ratio progression-free survival; HR OS, hazard ratio overall survival; ICER, incremental
cost-effectiveness ratio.
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Cost-effectiveness estimates are most sensitive to changes in
effectiveness data (hazard ratio) for overall survival, which is also
rather uncertain. Nonetheless, even assuming an optimistic sce-
nario, by applying the lower 95% conﬁdence value for the
hazard ratio for overall survival, the estimated cost per QALY is
£56,589 (Table 7) and remains at a level that may not be
regarded as offering value for money.
There are limitations with the analysis presented here due to
the scarcity of data available to estimate cost-effectiveness.
There is only one published randomized clinical trial of tem-
sirolimus compared with interferon-a in people with RCC
deemed to have poor prognosis [5]. Although, this is a large,
good quality trial, any biases within the trial will be reﬂected in
the cost-effectiveness analysis presented. We have presented
cost-effectiveness results for some subgroups, but clinical effec-
tiveness and therefore cost-effectiveness is highly uncertain for
some subgroups due to small numbers in the trial, in particular
for people with non-clear-cell RCC. A further limitation in the
cost-effectiveness analysis for subgroups, was that we were
unable to adjust baseline interferon-a survival for the patient
subgroups. Instead, we modelled only the treatment effect by
subgroup. If baseline survival differs substantially by patient
subgroup, then the cost-effectiveness estimates for these sub-
groups may become less accurate. There is an absence of pub-
lished data to inform on the costs associated with treatment of
RCC, and in the analysis we have used data based on UK clini-
cal practice. Nevertheless, we can see from Table 7 that cost-
effectiveness is largely determined by drug costs and drug
administration costs. Other items of resource use have less
impact on estimates of cost-effectiveness. More generally, as is
common in health technology assessment, we have access only
to secondary summary data, not individual patient data, to
model treatment efﬁcacy. Individual patient data on treatment
effectiveness may yield a more accurate assessment of cost-
effectiveness, but this information is unpublished. In particular,
we have estimated progression-free survival and overall survival
for baseline interferon-a by ﬁtting Weibull curves to Kaplan-
Meier data. Nevertheless, it is preferable to ﬁt Weibull curves
using the method of maximum likelihood using individual
patient data [19].
Once patients have progressed, we have not explicitly mod-
elled the use of second-line treatments, such as sunitinib or
sorafenib. Our implicit assumption is that the costs and beneﬁts
of later lines of treatment are equal between treatment arms.
Nevertheless, we believe that there is currently great uncertainty
in the UK around the use of these drugs, and drug sequences in
particular, because they are not currently recommended for use
in RCC in the UK. In addressing the question of the cost-
effectiveness of temsirolimus versus interferon-a, in the licensed
indication, we believe that our approach is reasonable and infor-
mative to decision makers. Furthermore, on speciﬁc issues, we
have assumed that the treatment effectiveness and dose intensities
of interferon-a and temsirolimus in normal clinical practice will
be similar to the values obtained in the pivotal RCT [5]. In the
probabilistic sensitivity analysis, we have not allowed for uncer-
tainty in dose intensities, due to lack of evidence. Inclusion of
uncertainty in this parameter would lead to greater uncertainty in
the estimates of cost-effectiveness. The effectiveness data in this
study were taken from a multinational clinical trial [5] and the
cost data were based on practice relevant to the UK NHS. There-
fore, our cost-effectiveness results are applicable to other coun-
tries only if the costs are similar to those in other countries.
Nonetheless, the modeling framework used here could be easily
adapted, with relevant cost data, to inform on health policy
decisions in other countries.
In keeping with the RCT by Hudes et al. [5], we have
assumed that interferon-a is an appropriate comparator treat-
ment for temsirolimus for patients with poor prognosis. Never-
theless, following the publication of the Percy QUATTRO study
[20] of immunotherapy in people with advanced RCC deemed to
have intermediate prognosis, there has been a re-evaluation of
the beneﬁts of interferon-a in this patient group with some
centres in the UK no longer offering treatment with interferon-a
to people with intermediate or poor prognosis. The study found
no signiﬁcant difference in survival between patients treated with
interferon-a and medroxyprogesterone acetate [20]. The only
available treatment option therefore becomes best supportive
care, which may be a more appropriate comparator in an eco-
nomic evaluation of temsirolimus. If we assume the clinical effec-
tiveness and quality of life associated with best supportive care is
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Figure 2 Cost-effectiveness acceptability curve
for temsirolimus versus interferon-a. The median
is shown by the dotted line.
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the same as that seen with interferon-a in the trial by Hudes et al.
[5] and we assume no drug (medroxyprogesterone acetate is very
cheap [12]) or drug administration costs and minimal medical
management (one GP consultation per month in PFS, one CT
scan per six months in PFS, blood tests monthly, and the same
costs in PD as for temsirolimus [3]), we estimate a cost per QALY
of approximately £109,000 for temsirolimus versus best suppor-
tive care.
We have presented cost-effectiveness analyses for several
patient subgroups, although there are limitations in data for
these estimates. Exploration of subgroup analyses is appropriate
when the characteristics of patients in subgroups are identiﬁed on
the basis of an a priori expectation of differential clinical or
cost-effectiveness due to known, biologically plausible mecha-
nisms, social characteristics or other clearly justiﬁed factors [8].
In the subgroup analysis presented here, the division of patients
by clear-cell and non–clear-cell for assessment of cost-
effectiveness has a clinical basis. Nevertheless, the clinical rel-
evance of the division by nephrectomy status is less clear and may
be confounded by other factors of disease status which underlie
the reasons behind some people not undergoing surgery, such
as the position of the primary tumour and the performance status
of the patient.
In an analysis presented in the UK (unpublished) Wyeth
reports cost-effectiveness at £55,814 per QALY, for temsirolimus
compared to interferon-a in patients with advanced poor-
prognosis RCC [4]. Wyeth use a similar cost-effectiveness mod-
elling framework to that reported here, but with transitions
between health states based on individual patient-level trial data,
which is arguably a richer source of data, offering a potentially
more accurate prediction of disease progression. Nevertheless,
Wyeth assume a resource use proﬁle for patients treated with
interferon-a that is much more costly than that found in UK
current practice. They also assumed a price of temsirolimus of
£515 per vial, rather than the latest list price of £620 per vial
[12]. We therefore suggest that their results may underestimate
the incremental costs associated with the administration and
acquisition of temsirolimus, and subsequently underestimate the
cost per QALY for temsirolimus compared to interferon-a.
This is the ﬁrst fully published cost-effectiveness analysis of
temsirolimus for treatment of RCC, and it has been produced by
an independent research team. In conclusion, we ﬁnd that
although temsirolimus signiﬁcantly improves progression-free
survival and overall survival compared to interferon-a in a popu-
lation of patients with advanced, poor prognosis renal cell car-
cinoma, treatment with temsirolimus may not be regarded as a
cost-effective use of resources in some health care settings.
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